SPATA20

Across TCGA pan-cancer cohorts, SPATA20 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPATA20 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SPATA20 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPATA20 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

LSCC, HNSC, and GBM are the cancer types where SPATA20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.260	0.943	<.001	20	view →
HNSC	DFS	Quartile	IV	0.862	0.511	.020	6	view →
GBM	OS	Median	All	0.263	0.551	.035	4	view →
PDAC	OS	Tertile	III,IV	1.000	0.527	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPATA20–LSCC (DFS)

Open the LSCC breakdown →